Alliance Global Partners initiated coverage of InspireMD (NYSE American:NSPR) with a “buy” rating and price target of 70 cents. The stock closed at 32 cent on Oct. 15. InspireMD has developed the CGuard EPS (Embolic...
Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...
Alliance Global Partners lowered its price target for Interpace Biosciences (NASDAQ:IDXG) to $9.25 from a reverse split-adjusted $21, but maintained its “buy” rating, after the company posted fourth quarter...
Alliance Global Partners downgraded Obalon Therapeutics (NASDAQ:OBLN) to “neutral” from “buy” and slashed its price target to 90 cents from $6.40 after the company moved to explore potential financial and strategic...
Alliance Global Partners downgraded Harvest Health & Recreation (CSE:HARV) to “neutral” from “buy” and slashed its price target to $1.60 (Canadian) from $8 after the company and Verano Holdings mutually agreed to...
Alliance Global Partners lowered its price target for T2 Biosystems (NASDAQ:TTOO) to $1.10 from $1.80 after the company released lower than expected first quarter results but added a COVID-19 program to its platform...
Alliance Global Partners raised its price target for OpGen (NASDAQ:OPGN) to $5 from $2.50 after the company reported better than expected fourth quarter results. The stock closed at $2.99 on March 24. OpGen also...
Alliance Global Partners upgraded Sensus Healthcare (NASDAQ:SRTS) to “buy” from “neutral” with a price target of $6 after the company reported fourth quarter results. The stock closed at $4.62 on Feb. 13. Analyst Ben...
Alliance Global Partners launched coverage of Harvest Health & Recreation (CSE:HARV) with a “buy” rating and price target of $8 (Canadian). The stock closed at $3.57 on Feb. 10. “We believe the company is well...
Alliance Global Partners initiated coverage of Curaleaf Holdings (CSE:CURA) with a “buy” rating and price target of $14 (Canadian). The stock closed at $8.56 on Feb. 10. “We view Curaleaf as well-positioned to succeed...